With the clin­ic in sight, Greg Verdine's start­up bags $178M for new class of tar­get­ed ther­a­pies

ARCH Ven­ture Part­ners is buy­ing in­to Greg Ver­dine’s vi­sion for a world where no tar­gets are off-lim­its — with the goal of fi­nal­ly push­ing the first drug in­to the clin­ic.

The size of the Se­ries D fi­nanc­ing — $178 mil­lion — match­es the grand am­bi­tions Fog­Phar­ma has sketched out with its He­li­con com­pounds, a new class of polypep­tide drugs it says com­bines the cell-pen­e­trat­ing ca­pac­i­ty of small mol­e­cules with the tar­get-en­gag­ing tenac­i­ty of bi­o­log­ics.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER